Publisher
Springer Berlin Heidelberg
Reference50 articles.
1. Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125–34. Erratum in: N Engl J Med 2007; 357(2): 203
2. Escudier B, Pluzanska A, Koralewski P et al.; AVOREN Trial investigators (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103–2111
3. Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271–2281
4. Ljungberg B, Hanbury DC, Kuczyk MA et al (2009) EAU guideline on renal cell carcinoma, European Association of Urology
5. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2007) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1): 289–296